Background and Objective: Cancer is a generic term for many diseases affecting any body part. Other terms used are malignant tumors and neoplasms. Disease elimination is an attempt to reduce the number of people who die from a particular cause. In practice, diseases like cancer can’t be eliminated, and their effects will vary from person-years lived to the amount of money spent on managing them. Thus, in the study, we have estimated the burden of cancer in terms of DALYs. Methods: To calculate YLL, we need the number of deaths due to cancers and standard life expectancy. Firstly, the age-sex-specific death rate (ASDR) from SRS was multiplied by the projected population, giving the age-sex-specific numbers of total deaths. Then, the number of cancer deaths was multiplied by standard life expectancy, giving YLL. To calculate YLD, we have multiplied the prevalence cases of cancer and the disability weights. Disability was estimated based on data for countries classified as Established Market Economies (EME) in the GBD study. Then the prevalence cases of cancer were multiplied by disability weights to obtain YLD. And lastly, DALYs were estimated by adding YLL and YLD. Results: The total number of DALYs for three leading cancer sites was 5380.95 and 4735.57 per 100000 in males and females, respectively. Ranked by the age-standardized DALY rate, the top three cancers were lung (2500.58/100000 population), mouth (1430.83/100000 population), and stomach (1449.53/100000 population) in males and breast (2622.33/100000 population), cervical (1346.38/100000 population), and ovary cancer (766.86/100000 population) in females. Conclusions: This disease burden estimate approach is incredibly beneficial for monitoring services and conducting health economic analyses such as cost-effectiveness studies. In addition, once results from DALY analyses are available in other developing countries, similarities and differences should be examined in more detail.